Business Description
Rocket Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US77313F1066
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 10.81 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.4 | |||||
3-Year EPS without NRI Growth Rate | -5 | |||||
3-Year FCF Growth Rate | -10.4 | |||||
3-Year Book Growth Rate | -12.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 15.94 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.43 | |||||
9-Day RSI | 45.95 | |||||
14-Day RSI | 45.78 | |||||
6-1 Month Momentum % | -33.65 | |||||
12-1 Month Momentum % | -26.17 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.79 | |||||
Quick Ratio | 7.79 | |||||
Cash Ratio | 7.42 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14 | |||||
Shareholder Yield % | -11.12 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -55.96 | |||||
ROA % | -49.22 | |||||
ROIC % | -159.12 | |||||
3-Year ROIIC % | -147.02 | |||||
ROC (Joel Greenblatt) % | -291.07 | |||||
ROCE % | -52.68 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.54 | |||||
Price-to-Tangible-Book | 5.3 | |||||
EV-to-EBIT | -6.86 | |||||
EV-to-Forward-EBIT | -5.06 | |||||
EV-to-EBITDA | -7.1 | |||||
EV-to-Forward-EBITDA | -5.13 | |||||
EV-to-Forward-Revenue | 103.05 | |||||
EV-to-FCF | -7.1 | |||||
Price-to-Net-Current-Asset-Value | 7.36 | |||||
Price-to-Net-Cash | 7.8 | |||||
Earnings Yield (Greenblatt) % | -14.59 | |||||
FCF Yield % | -10.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Rocket Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.584 | ||
Beta | 0.82 | ||
Volatility % | 68.08 | ||
14-Day RSI | 45.78 | ||
14-Day ATR (€) | 0.772759 | ||
20-Day SMA (€) | 16.97975 | ||
12-1 Month Momentum % | -26.17 | ||
52-Week Range (€) | 15.7 - 29.91 | ||
Shares Outstanding (Mil) | 90.98 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Rocket Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Rocket Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Rocket Pharmaceuticals Inc Frequently Asked Questions
What is Rocket Pharmaceuticals Inc(STU:9IP1)'s stock price today?
When is next earnings date of Rocket Pharmaceuticals Inc(STU:9IP1)?
Does Rocket Pharmaceuticals Inc(STU:9IP1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |